These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30370398)

  • 1. Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.
    Yu Y; Ryan BM; Thomas A; Morrow B; Zhang J; Kang Z; Zingone A; Onda M; Hassan R; Pastan I; Cao L
    J Appl Lab Med; 2018 Sep; 3(2):166-177. PubMed ID: 30370398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant polypeptide of the megakaryocyte potentiating factor is a potential biomarker in plasma for the detection of mesothelioma.
    Raiko I; Rihs HP; Gleichenhagen J; Sander I; Kollmeier J; Lehnert M; Brüning T; Johnen G
    Biochem Biophys Res Commun; 2017 Apr; 486(2):526-532. PubMed ID: 28322788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
    Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
    J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
    Creaney J; Sneddon S; Dick IM; Dare H; Boudville N; Musk AW; Skates SJ; Robinson BW
    Dis Markers; 2013; 35(2):119-27. PubMed ID: 24167356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study.
    Hollevoet K; Van Cleemput J; Thimpont J; De Vuyst P; Bosquée L; Nackaerts K; Germonpré P; Vansteelandt S; Kishi Y; Delanghe JR; van Meerbeeck JP
    J Thorac Oncol; 2011 May; 6(5):889-95. PubMed ID: 21358346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.
    Hollevoet K; Nackaerts K; Thas O; Thimpont J; Germonpré P; De Vuyst P; Bosquée L; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
    Chest; 2012 Feb; 141(2):477-484. PubMed ID: 21737491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
    Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M
    BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.
    Onda M; Nagata S; Ho M; Bera TK; Hassan R; Alexander RH; Pastan I
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4225-31. PubMed ID: 16857795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
    Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice.
    Linch M; Gennatas S; Kazikin S; Iqbal J; Gunapala R; Priest K; Severn J; Norton A; Ayite B; Bhosle J; O'Brien M; Popat S
    BMC Cancer; 2014 Sep; 14():674. PubMed ID: 25227779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
    de Fonseka D; Arnold DT; Stadon L; Morley A; Keenan E; Darby M; Armstrong L; Virgo P; Maskell NA
    BMC Cancer; 2018 Feb; 18(1):199. PubMed ID: 29454314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
    Pantazopoulos I; Boura P; Xanthos T; Syrigos K
    Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
    Santarelli L; Staffolani S; Strafella E; Nocchi L; Manzella N; Grossi P; Bracci M; Pignotti E; Alleva R; Borghi B; Pompili C; Sabbatini A; Rubini C; Zuccatosta L; Bichisecchi E; Valentino M; Horwood K; Comar M; Bovenzi M; Dong LF; Neuzil J; Amati M; Tomasetti M
    Lung Cancer; 2015 Dec; 90(3):457-64. PubMed ID: 26431916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study.
    Casjens S; Weber DG; Johnen G; Raiko I; Taeger D; Meinig C; Moebus S; Jöckel KH; Brüning T; Pesch B
    BMJ Open; 2017 Oct; 7(10):e017104. PubMed ID: 29025836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of MiR-103a-3p and mesothelin improves the biomarker performance of malignant mesothelioma diagnosis.
    Weber DG; Casjens S; Johnen G; Bryk O; Raiko I; Pesch B; Kollmeier J; Bauer TT; Brüning T
    PLoS One; 2014; 9(12):e114483. PubMed ID: 25469901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.